Have a question for this guest? Submit it here.
It might end up on air!
Alice Valder Curran, a Life Sciences Regulatory Expert, Business & Legal Advisor, Executive Leader and Partner at Hogan Lovells, will share the story behind her title with us on February 28, 2023.
Alice advises pharmaceutical manufacturers regarding drug pricing matters, with a particular emphasis on compliance obligations under the Medicaid Drug Rebate Program, the Medicare average sales price (ASP) reporting requirement, and the Health Resources and Services Administration (HRSA) 340B Drug Pricing Program.
She works directly with C-Suite executives on the government pricing (GP) implications of common commercial strategies, and the strategic role that these programs can play for certain drugs. Alice also works with commercial and finance personnel on the nuts and bolts of implementing GP obligations. She teams with her white-collar colleagues on GP-related enforcement matters, often taking the lead when interacting with enforcement authorities on the specifics of Medicaid, Medicare, and 340B programs.
Alice counsels pharmaceutical companies on the treatment of various commercial strategies in the government pricing calculations – from wholesaler, GPO, and managed care proposals, to product launch strategies and patient programs. Working with manufacturers of all sizes and maturities, Alice brings valuable insight on the strengths and weaknesses of commercialization trends across the industry. Alice develops GP policy documents, “reasonable assumptions” in support of calculation methodologies, and Centers for Medicare and Medicaid Services (CMS) and HRSA 340B recalculation disclosure submissions.
Policy advocacy rounds out Alice’s practice. Her knowledge of these programs and how they impact a manufacturer’s day-to-day operations, as well as its strategic interests, make Alice a sought-after resource for evaluating legislative and policy proposals. She also represents manufacturers directly before CMS and HRSA on general policy issues, as well as advocating for company-specific actions.